Lucja Kudla

Lucja Kudla

Auto-generated profile, based on publicly available information

Lucja Kudla

Maj Institute of Pharmacology Polish Academy of Sciences, Department of Molecular Neuropharmacology, Krakow, Poland

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 July 2019 in British Journal of Pharmacology
Verified
Journal Article
Open access
PDF file
LKLucja Kudla
Lucja Kudla
RBRyszard Bugno
Ryszard Bugno
USUrszula Skupio
Urszula Skupio
LWLucja Wiktorowska
Lucja Wiktorowska
WSWojciech Solecki
Wojciech Solecki
RPRyszard Przewlocki
Ryszard Przewlocki
Background and Purpose: The concept of opioid ligands biased towards the G protein pathway with minimal recruitment of β‐arrestin‐2 is a promising approach for the development of novel, efficient, and potentially nonaddictive opioid therapeutics. A recently discovered biased μ‐opioid receptor agonist, PZM21, showed analgesic effects with reduced side effects. Here, we aimed to further investigate the behavioural and biochemical properties of PZM21.Experiment Approach: We evaluated antinociceptive effects of systemic and intrathecal PZM21 administration. Its addiction‐like properties were determined using several behavioural approaches: conditioned place preference, locomotor sensitization, precipitated withdrawal, and self‐administration. Also, effects of PZM21 on morphine‐induced antinociception, tolerance, and reward were assessed. Effects of PZM21 on striatal release of monoamines were evaluated using brain microdialysis.Key Results: PZM21 caused long‐lasting dose‐dependent antinociception. It did not induce reward‐ and reinforcement‐related behaviour; however, its repeated administration led to antinociceptive tolerance and naloxone‐precipitated withdrawal symptoms. Pretreatment with PZM21 enhanced morphine‐induced antinociception and attenuated the expression of morphine reward. In comparison to morphine, PZM21 administration induced a moderate release of dopamine and a robust release of 5‐HT in the striatum.Conclusions and Implications: PZM21 exhibited antinociceptive efficacy, without rewarding or reinforcing properties. However, its clinical application may be restricted, as it induces tolerance and withdrawal symptoms. Notably, its ability to diminish morphine reward implies that PZM21 may be useful in treatment of opioid use disorders.

9 April 2021 in Pharmacological Reports
Verified
Journal Article
Open access
PDF file
LKLucja Kudla
Lucja Kudla
RPRyszard Przewlocki
Ryszard Przewlocki
Opioid analgesics remain a gold standard for the treatment of moderate to severe pain. However, their clinical utility is seriously limited by a range of adverse effects. Among them, their high-addictive potential appears as very important, especially in the context of the opioid epidemic. Therefore, the development of safer opioid analgesics with low abuse potential appears as a challenging problem for opioid research. Among the last few decades, different approaches to the discovery of novel opioid drugs have been assessed. One of the most promising is the development of G protein-biased opioid agonists, which can activate only selected intracellular signaling pathways. To date, discoveries of several biased agonists acting via μ-opioid receptor were reported. According to the experimental data, such ligands may be devoid of at least some of the opioid side effects, such as respiratory depression or constipation. Nevertheless, most data regarding the addictive properties of biased μ-opioid receptor agonists are inconsistent. A global problem connected with opioid abuse also requires the search for effective pharmacotherapy for opioid addiction, which is another potential application of biased compounds. This review discusses the state-of-the-art on addictive properties of G protein-biased μ-opioid receptor agonists as well as we analyze whether these compounds can diminish any symptoms of opioid addiction. Finally, we provide a critical view on recent data connected with biased signaling and its implications to in vivo manifestations of addiction. Graphic abstract

1 December 2021 in European Neuropsychopharmacology
Verified
Journal Article
Closed access
LKL. Kudla
L. Kudla
RBRyszard Bugno
Ryszard Bugno
ABAndrzej Bojarski
Andrzej Bojarski
RPRyszard Przewlocki
Ryszard Przewlocki